Navigation Links
Shire's INTUNIV (Guanfacine) extended release in children with ADHD and oppositional symptoms
Date:5/18/2009

San Francisco, CA May 18, 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced new findings on INTUNIV (guanfacine) extended release, a selective alpha-2A-agonist, at a major psychiatric meeting. This randomized placebo controlled trial met its primary objective, which was to evaluate the effects of INTUNIV on oppositional symptoms in children aged 6 to 12 years with a diagnosis of ADHD and the presence of oppositional symptoms. The data presented today on this investigational compound reviewed secondary efficacy measures from three different rating scales.

"A significant number of pediatric ADHD patients present with behaviors such as anger, resentfulness, defiance, and arguing with adults. It can be complicated for physicians and caregivers to find the right medication to control symptoms for children with ADHD exhibiting these behaviors," said Daniel Connor, MD, professor and division chief of child and adolescent psychiatry at the University of Connecticut Medical School. "When considered with the primary efficacy results of the current study, these data provide additional support for the clinical efficacy of INTUNIV for treating ADHD in this patient population."

On January 26, 2009, Shire filed a resubmission to the US Food and Drug Administration (FDA) of the New Drug Application to support approval for the treatment of ADHD in children and adolescents. Once available, INTUNIV will be the first selective alpha-2A receptor agonist approved for the treatment of ADHD.

INTUNIV Demonstrated Significant Efficacy in Secondary Endpoints

In this randomized, placebo-controlled, flexible-dose study, INTUNIV demonstrated significant ADHD symptom improvement in patients with oppositional symptoms as measured by the ADHD Rating Scale-IV (ADHD-RS-IV), a scale frequently used in ADHD clinical trials. In results from this study presented today, INTUNIV also demonstrated sy
'/>"/>

Contact: Debra Gemme
debra.gemme@porternovelli.com
212-601-8342
Porter Novelli
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
2. FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
3. New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
4. Neuromed Announces Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial
5. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Extended Release (ER) Phase 3 Clinical Data Presented at World Institute of Pain 5th Annual World Congress
6. Cipher receives tentative FDA approval for extended-release tramadol capsules
7. Bioniche Warrants Expiration Date to be Extended
8. Teaching Hospitals Post-Op Gains Not Extended to Blacks
9. Stroke therapy window might be extended past nine hours for some
10. Instrumentation Laboratory Wins Extended Agreement With MedAssets Supply Chain Systems for Critical Care Portfolio
11. Get Screened Video Contest Deadline Extended to Jan. 30
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... (PRWEB) May 29, 2015 Healthpointe’s ... expertise to the Los Angeles County clinics including ... procedures are now being offered at all Healthpointe ... County, and San Bernardino County. , As ... neurons send electrical impulses throughout the body ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Healthpointe is ... Joint Fluid Therapy (JFT) at their clinics in Orange ... injectable treatment that assists in diminishing pain for patients ... Dr. Stanley Katz and Dr. Neil Katz of Healthpointe. ... sodium hyaluronate (also known as hyaluronic acid) a natural ...
(Date:5/29/2015)... CA (PRWEB) May 29, 2015 For the ... (USAU) to bring the Denver youth ultimate community an opportunity ... learning and individual improvement. The mission of the USAU Nike ... boys and girls to improve, build character, and make lifelong ... for boys and girls of all skill and ability levels, ...
(Date:5/29/2015)... News: 2015-2016 Oil Market Forecast, Company: Carson Energy, ... , In July, 2014, the price of oil ... US shale production and increased production from Saudi Arabia. ... from US shale producers, started producing close to their ... into the marketplace, they could push oil prices below ...
(Date:5/29/2015)... May 29, 2015 Wimbledon Health Partners, ... electrocardiogram (EKG), echocardiogram and NCV testing, is proud ... guidelines for EKG interpretation of athletes. ... of death during athletic activity. New findings presented in ... discussion to improve cardiac safety in athletes. Physiologic adaptations ...
Breaking Medicine News(10 mins):Health News:Healthpointe Is Now Offering EMG and NCV Diagnostics at All Clinics throughout Southern California. 2Health News:Healthpointe is Now Offering Supartz Joint Fluid Therapy at their Anaheim Clinic and La Mirada Clinic. 2Health News:US Sports Camps, Nike Sports Camps, and USA Ultimate Host Third Summer of Ultimate Camp in Denver 2Health News:Breaking News: Carson Energy Releases 2015-2016 Oil Forecast 2Health News:Wimbledon Health Partners Incorporates Updated ‘Seattle Criteria’ for EKG Interpretation of Athletes 2Health News:Wimbledon Health Partners Incorporates Updated ‘Seattle Criteria’ for EKG Interpretation of Athletes 3
... Institute of Medicine recommends ways to avert an impending health care ... number of health care workers with the skills to meet their ... older by 2030 as the baby boom generation ages. The ... do to ensure that older Americans get the best care possible. ...
... 11 /Xinhua-PRNewswire-FirstCall/ -- Linkwell,Corporation (Linkwell) (OTC Bulletin ... of healthcare related disinfectants in China,announced today ... Hi-Tech Company, Ltd., (LiKang Disinfectant) was selected ... Ministry of Human Resources and,Social Security (MOHRSS) ...
... to evaluate palpable breast lesions, they can rule out ... conducted by researchers at Baystate Health in Springfield, MA. ... protocol. , We were interested in finding out ... together, in excluding breast cancer in women with palpable ...
... Registration is now,open for CleanMed 2008, ... practices and green building. The event is,produced ... Harm,along with partners Consorta, the Heinz Endowments, ... Center., CleanMed attracts major health care ...
... Set for June as Plan Moves Forward, HARRISBURG, ... provide input on Pennsylvania,s new State Plan on Aging., ... to help the,Department of Aging prioritize the needs and ... wellness and fitness programs, legal,assistance, and long-term living options. ...
... cancer patients who had an MRI examination before their initial ... out of Yale University School of Medicine. , ... treatment and 374 who did not undergo an MRI examination. ... Carol Lee, MD, an author of the study, now at ...
Cached Medicine News:Health News:Linkwell Corporation Selected to Train and License all Disinfectant and Pest Control Professionals in China and for the Beijing Olympics 2Health News:Linkwell Corporation Selected to Train and License all Disinfectant and Pest Control Professionals in China and for the Beijing Olympics 3Health News:Mammography plus sonography can help rule out breast cancer in patients with palpable lesions 2Health News:Creating Healing Environments: Healthcare Industry's Largest Sustainability Conference to be Held May 20-22 in Pittsburgh 2Health News:April 15 is Deadline for Input on State Aging Plan 2
(Date:5/28/2015)... MOUNTAIN VIEW, Calif. , May 28, 2015  IRIDEX ... Officer and Chief Financial Officer James H. Mackaness ... Wednesday, June 3, 2015, at 9:00 am PT in ... webcast of the presentation may be accessed on the Event ... www.iridex.com .  A replay of the webcast will be available ...
(Date:5/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/pph6hl/united_states ... "United States Medical Adhesives Market Forecast and Opportunities, ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , , The market ... States is projected to register 9% ... manufacturers across the US are expanding their production ...
(Date:5/28/2015)... The Parenteral Drug Association (PDA) proudly ... of the Johnson & Johnson Kilmer Conference on ... Johnson & Johnson (J&J) is reviving the conference ... endoscopes. J&J ran 8 conferences on sterilization, validation ... on advances in sterilization and other topics. ...
Breaking Medicine Technology:United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 2United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 3PDA Announces Support for the Johnson & Johnson Kilmer Conference 2
... VEGAS, June 27, 2011 Gamma Pharmaceuticals, Inc. (NASDAQ: ... own branded products through wholesalers and direct to retailers, ... Company has completed a sale and revenue collection cycle ... Company,s energy gel products to a Northeast distribution center ...
... Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today ... based on tumor reprogramming will be presented at the ... 14th World Conference on Lung Cancer meeting ( www.2011worldlungcancer.org ...   "The data presentations from both lung ...
Cached Medicine Technology:Gamma Pharmaceuticals, Inc. Completes Sale and Books Revenue with National Pharmacy Chain 2Gamma Pharmaceuticals, Inc. Completes Sale and Books Revenue with National Pharmacy Chain 3Syndax Pharmaceuticals Announces Entinostat Data from Two Lung Cancer Clinical Trials at Upcoming World Lung Conference 2Syndax Pharmaceuticals Announces Entinostat Data from Two Lung Cancer Clinical Trials at Upcoming World Lung Conference 3Syndax Pharmaceuticals Announces Entinostat Data from Two Lung Cancer Clinical Trials at Upcoming World Lung Conference 4
... Rapid Toxin A Test gives your laboratory clear-cut ... it might be C. difficile, you can't afford ... a few tests a day or sends out ... Toxin A C. difficile Rapid Toxin A Test ...
... C. Diff A is a ... qualitative detection of Clostridium difficile ... , ,Clearview C. Diff A ... to provide fast, accurate detection ...
... come back with better resolution, accuracy and ... 25 or 31 rings (same as TMS-1), ... provides high accuracy & repeatability. The small ... & provides extensive corneal coverage. The low ...
... The OCULUS Pachycam is the first ... built-in keratometer. The OCULUS Pachycam ... (intra ocular pressure) in accordance with ... "real IOP. The OCULUS Pachycam ...
Medicine Products: